| Code | CSB-RA011664MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to FB-704A, targeting interleukin-6 (IL-6), a pleiotropic cytokine that plays a central role in immune regulation and inflammatory responses. IL-6 is secreted by various cell types including T cells, macrophages, and fibroblasts, and functions through both classical and trans-signaling pathways to mediate acute phase responses, hematopoiesis, and immune cell differentiation. Dysregulated IL-6 signaling is implicated in numerous pathological conditions, including rheumatoid arthritis, inflammatory bowel disease, cytokine release syndrome, and various malignancies where it promotes tumor growth, angiogenesis, and metastasis.
FB-704A represents an investigational therapeutic antibody designed to neutralize IL-6 activity by blocking its interaction with IL-6 receptors. This biosimilar provides researchers with a valuable tool for investigating IL-6-mediated signaling cascades, studying cytokine networks in inflammatory disease models, and exploring potential therapeutic interventions in IL-6-driven pathologies. The antibody enables detailed mechanistic studies of IL-6 biology and supports preclinical research in immunology, oncology, and inflammatory disease contexts.
There are currently no reviews for this product.